CARA News and Press, Cara Therapeutics Inc. From 04/29/21

Shares of Cara Therapeutics (NASDAQ: CARA) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study evaluating oral Korsuva in treating moderate-to-severe pruritis in patients with atopic dermatitis. ...

Gainers: Galera Therapeutics (GRTX) +26%, Ocular Therapeutix (OCUL) +17%, Capricor Therapeutics (CAPR) +15%, AtriCure (ATRC) +12%, Atossa Therapeutics (ATOS) +14%.Losers: Adverum Biotechnologies (ADVM) -60%, Cara Therapeutics (CARA) -44%,...

Cara Therapeutics (CARA) has lost ~36.8% in the pre-market after the company announced that its Oral KORSUVA (difelikefalin tablets) failed to meet the primary endpoint in Phase 2 dose-ranging clinical trial in atopic dermatitis patients with moderate-to-severe pruritus.The randomiz...

Adverum Biotechnologies (ADVM) -54% after updates on ADVM-022 diabetic macular edema trial.Cara Therapeutics (CARA) -36% after announces topline results from KARE Phase 2 dose-ranging trial of oral KORSUVA™ in atopic dermatitis patients with moderate-to-severe pruritus.T...

– Study did not meet Primary Endpoint of worst-itch NRS change from baseline at week 12 or Secondary Endpoint of 4-point responder analysis in the ITT patient population – Study achieved Primary Endpoint of worst-itch NRS change and Secondary Endpoint of 4-poin...

CARA has a PDUFA on August 23 for lead candidate KORSUVA in CKD-HD patients suffering from pruritus. The market is large and there's an unmet need. This was a great stock to buy 4 months ago. For further details see: Cara Therapeutics: Upcoming PDUFA May See Some Upside ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Weed stocks have had a topsy-turvy 12 months. The election of President Joe Biden raised hopes of ending the federal prohibition of pot through a Congressional bill. However, in the months since the inauguration, it has bec...

STAMFORD, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today a...

Gainers: Brooklyn ImmunoTherapeutics (BTX) +45%, Greenwich LifeSciences (GLSI) +16%, PAVmed (PAVM) +15%, SeaSpine Holdings (SPNE) +14%, Cara Therapeutics (CARA) +14%.Losers: Scholar Rock (SRRK) -14%, Chembio Diagnostics (CEMI) -13%, Harmo...

Shares of Cara Therapeutics (NASDAQ: CARA) were soaring 13.1% higher as of 10:45 a.m. EDT on Tuesday. The big gain came after S&P Global division S&P Dow Jones Indices announced that Cara will replace MTS Systems in the S&P SmallCap 600 index . The nice j...